Gerresheimer To Collaborate With Aptar Digital To Develop Integrated Solution For Cancer Therapy

(RTTNews) - Gerresheimer AG (GRRMF.PK) Thursday announced a collaboration with Aptar Digital Health to develop an integrated solution for cancer therapy management. Aptar Pharma's Digital Health division is part of AptarGroup, Inc. (ATR).

As part of the collaboration, the Gx SensAir on-body drug delivery device will be connected to Aptar Digital Health's software-as-a-medical device platform to improve the treatment of cancer patients. Gx SensAir can be used to administer large molecule biopharmaceuticals subcutaneously.

The integrated solution will help better manage adverse effects, and make it easier to monitor patients remotely.

The integrated solution will first be designed for targeted anticancer therapies such as PD-1/PDL-1, CTLA-4, with the potential to expand to all therapies delivered subcutaneously.